BR112012006642A2 - composição oftálmica aquosa injetável e método para uso da mesma - Google Patents

composição oftálmica aquosa injetável e método para uso da mesma

Info

Publication number
BR112012006642A2
BR112012006642A2 BR112012006642A BR112012006642A BR112012006642A2 BR 112012006642 A2 BR112012006642 A2 BR 112012006642A2 BR 112012006642 A BR112012006642 A BR 112012006642A BR 112012006642 A BR112012006642 A BR 112012006642A BR 112012006642 A2 BR112012006642 A2 BR 112012006642A2
Authority
BR
Brazil
Prior art keywords
ophthalmic composition
injectable aqueous
aqueous ophthalmic
mass
creation
Prior art date
Application number
BR112012006642A
Other languages
English (en)
Inventor
Ernesto J Castillo
Massod A Chowhan
Thomas C Hohman
Wesley Wehsin Han
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BR112012006642A2 publication Critical patent/BR112012006642A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição oftálmica aquosa injetável e método para uso da mesma. a presente invenção refere-se ao fornecimento de uma composição oftálmica adequada para injeção intravítrea. a composição inclui uma quantidade de agentes de complexação que reage com um ou mais componentes endógenos (por exemplo, ácido hialurônico) no olho para formar uma massa de viscosidade melhorada. essa massa pode auxiliar na criação de um perfil de liberação desejável de agente terepêutico.
BR112012006642A 2009-09-23 2010-09-21 composição oftálmica aquosa injetável e método para uso da mesma BR112012006642A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24491609P 2009-09-23 2009-09-23
PCT/US2010/049623 WO2011037908A1 (en) 2009-09-23 2010-09-21 Injectable aqueous ophthalmic composition and method of use therefor

Publications (1)

Publication Number Publication Date
BR112012006642A2 true BR112012006642A2 (pt) 2016-05-03

Family

ID=43034434

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006642A BR112012006642A2 (pt) 2009-09-23 2010-09-21 composição oftálmica aquosa injetável e método para uso da mesma

Country Status (15)

Country Link
US (3) US20110071091A1 (pt)
EP (1) EP2480205B1 (pt)
JP (2) JP5732058B2 (pt)
KR (2) KR20170008895A (pt)
CN (1) CN102695497B (pt)
AR (1) AR078293A1 (pt)
AU (1) AU2010298480B2 (pt)
BR (1) BR112012006642A2 (pt)
CA (1) CA2772795A1 (pt)
ES (1) ES2568462T3 (pt)
MX (1) MX2012003196A (pt)
PL (1) PL2480205T3 (pt)
TW (1) TWI492769B (pt)
WO (1) WO2011037908A1 (pt)
ZA (1) ZA201201438B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US20140178327A1 (en) 2012-12-21 2014-06-26 Coopervision International Holding Company, Lp Antimicrobial Ophthalmic Devices
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
KR102435676B1 (ko) 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) * 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
WO2015168140A1 (en) * 2014-04-28 2015-11-05 Hampton Technologies Ophthalmic compositions and methods for treating eyes
US20150366311A1 (en) 2014-06-19 2015-12-24 Coopervision International Holding Company, Lp Protection of Contact Lenses from Microbial Contamination Caused by Handling
WO2016197005A1 (en) * 2015-06-05 2016-12-08 Kato Pharmaceuticals, Inc. Extended release urea compositions
AU2016311158A1 (en) 2015-08-21 2018-04-05 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. POLYTHERAPY OF DISORDERS AND INFLAMMATORY EYE DISEASES
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
JP2021535112A (ja) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS
US20220133697A1 (en) * 2018-12-05 2022-05-05 Aldeyra Therapeutics, Inc. Injectable formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU604236B2 (en) * 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
BRPI0516082A (pt) 2004-09-24 2008-08-19 Hercules Inc poligalactomananos catiÈnicos de alto ds para produtos de cuidado com a pele
ES2564194T3 (es) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Formulaciones líquidas para el tratamiento de enfermedades o dolencias
CN100433805C (zh) * 2005-06-29 2008-11-12 上海广电（集团）有限公司中央研究院 一种数字电视接收机及其信号传递方法
WO2007044668A2 (en) * 2005-10-08 2007-04-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
RU2505311C2 (ru) * 2007-10-02 2014-01-27 Потентия Фармасьютикалз, Инк. Пролонгированная доставка аналогов компстатина из гелей
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
US8530189B2 (en) 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
BR112012028308B1 (pt) * 2010-05-05 2021-09-28 Alcon Inc. Formulações oftálmicas de galactomanano estabilizadas, e seu método de fabricação

Also Published As

Publication number Publication date
JP5732058B2 (ja) 2015-06-10
US20140094419A1 (en) 2014-04-03
CN102695497A (zh) 2012-09-26
PL2480205T3 (pl) 2016-09-30
WO2011037908A1 (en) 2011-03-31
KR20170008895A (ko) 2017-01-24
ES2568462T3 (es) 2016-04-29
US20110071091A1 (en) 2011-03-24
US9446093B2 (en) 2016-09-20
TW201111003A (en) 2011-04-01
AU2010298480A1 (en) 2012-03-29
CA2772795A1 (en) 2011-03-31
EP2480205B1 (en) 2016-03-16
TWI492769B (zh) 2015-07-21
EP2480205A1 (en) 2012-08-01
JP2013505934A (ja) 2013-02-21
US20160361254A1 (en) 2016-12-15
AR078293A1 (es) 2011-10-26
ZA201201438B (en) 2013-05-29
JP2015129194A (ja) 2015-07-16
CN102695497B (zh) 2016-01-06
AU2010298480B2 (en) 2014-08-07
KR20120069741A (ko) 2012-06-28
MX2012003196A (es) 2012-04-30

Similar Documents

Publication Publication Date Title
BR112012006642A2 (pt) composição oftálmica aquosa injetável e método para uso da mesma
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112014027204A2 (pt) conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos
BR112014012524A2 (pt) composições compreendendo um componente de estabilidade do prazo de validade
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BR112014017716A8 (pt) composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol
BR112014003903A2 (pt) composições dentais que compreendem agentes de adição fragmentação
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
BR112013017845A2 (pt) agente antidiabético de abaixamento de lipídio
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
BRPI0909630B8 (pt) composição em suspensão aquosa particularmente adequada para injeção dentro do olho
BRPI0718176B8 (pt) formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida
BR112015012972A2 (pt) método para tratar uma formação subterrânea, composição para tratamento de uma formação subterrânea, e, método para preparo de uma composição aquosa para tratamento de uma formação subterrânea
BR112012026724A2 (pt) combinação de fármcos com pró-fármacos ligados à proteína
BR112014015084A2 (pt) chocolate aerado
BR112015023387A2 (pt) composições lipídicas de racecodotril
BR112014012735A8 (pt) dispersões aquosas de polifenol de zero teor de caloria
BR112015022218A2 (pt) composições e sua utilização para tratar complicações da hemorragia subaracnóidea aneurismática
BR112015021332A2 (pt) sal de sódio de ácido (2s, 5r)-6-benzilóxi-7-oxo-1,6-diaza-biciclo [3.2.1] octano-2-carboxílico e sua preparação
BR112013019394A2 (pt) uso de um agente
BR112013010367A2 (pt) métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina
BR112012017202A2 (pt) composição transparente ou translúcida
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2480 DE 17-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.